Have a personal or library account? Click to login
Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management Cover

Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management

Open Access
|Apr 2020

References

  1. Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol 2012;50:458–70. doi: 10.3109/15563650.2012.702218
  2. Carter LP, Pardi D, Gorsline J, Griffiths RR. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem® Differences in characteristics and misuse. Drug Alcohol Depend 2009;104:1–10. doi: 10.1016/J. DRUGALCDEP.2009.04.012
  3. Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend 2001;63:1–22. doi: 10.1016/ S0376-8716(00)00191-5
  4. Busardò FP, Kyriakou C, Napoletano S, Marinelli E, Zaami S. Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome. Eur Rev Med Pharmacol Sci 2015;19:4654–63. PMID: 26698265
  5. Wood DM, Brailsford AD, Dargan PI. Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal 2011;3:417–25. doi: 10.1002/dta.292
  6. Rambourg-Schepens MO, Buffet M, Durak C, Mathieu-Nolf M. Gamma butyrolactone poisoning and its similarities to gamma hydroxybutyric acid: two case reports. Vet Hum Toxicol 1997;39:234–5. PMID: 9251175
  7. Busardò FP, Gottardi M, Tini A, Minutillo A, Sirignano A, Marinelli E, Zaami S. Replacing GHB with GBL in recreational settings: a new trend in chemsex. Curr Drug Metab 2018;19:1080–5. doi: 10.2174/13892002196661809 25090834
  8. Hibell B, Andersson B, Bjarnason T, Ahlström S, Balakireva O, Kokkevi A, Morgan M. The ESPAD report 2003 : alcohol and other drug use among students in 35 European countries. Stockholm: Swedish Council for Information on Alcohol and Other Drugs (CAN); 2004.
  9. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the Risk Assessment of GHB in the Framework of the Joint Action on New Synthetic Drugs. Luxembourg: Office for Official Publications of the European Communities; 2002.
  10. Knudsen K, Greter J, Verdicchio M. High mortality rates among GHB abusers in Western Sweden. Clin Toxicol 2008;46:187–92. doi: 10.1080/15563650701263633
  11. Wood DM, Nicolaou M, Dargan PI. Epidemiology of Recreational Drug Toxicity in a Nightclub Environment. Subst Use Misuse 2009;44:1495–502. doi: 10.1080/10826080802543580
  12. Giorgetti R, Tagliabracci A, Schifano F, Zaami S, Marinelli E, Busardò FP. When “chems” meet sex: a rising phenomenon called “chemsex”. Curr Neuropharmacol 2017;15:762–70. doi: 10.2174/1570159X15666161117151148
  13. Marinelli S, Berretta P, Pacifici R, Del Rio A. Sex enhancers: challenges, threats and the need for targeted measures. Clin Ter 2019;170(3):e181–3. doi: 10.7417/CT.2019.2130
  14. Zaami S, Giorgetti R, Pichini S, Pantano F, Marinelli E, Busardò FP. Synthetic cathinones related fatalities: an update. Eur Rev Med Pharmacol Sci 2018;22:268–74. doi: 10.26355/eurrev_201801_14129
  15. Gentili S, Mortali C, Mastrobattista L, Berretta P, Zaami S. Determination of different recreational drugs in sweat by headspace solid-phase microextraction gas chromatography mass spectrometry (HS-SPME GC/MS): Application to drugged drivers. J Pharm Biomed Anal 2016;129:282–7. doi: 10.1016/j.jpba.2016.07.018
  16. Gamma Hydroxy Butyrate Usage, Effects and UK Prices [displayed 10 July 2019]. Available at http://www.idmu.co.uk/oldsite/ghb.htm
  17. McCambridge J, Mitcheson L, Winstock A, Hunt N. Five-year trends in patterns of drug use among people who use stimulants in dance contexts in the United Kingdom. Addiction 2005;100:1140–9. doi: 10.1111/j.1360-0443.2005.01127.x
  18. Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Use. Overview of Key Findings, 2011. Ann Arbor (MI): Institute for Social Research The University of Michigan; 2012.
  19. Busardò FP, Bertol E, Vaiano F, Baglio G, Montana A, Barbera N, Zaami S, Romano G. Post mortem concentrations of endogenous gamma hydroxybutyric acid (GHB) and in vitro formation in stored blood and urine samples. Forensic Sci Int 2014;243:144–8. doi: 10.1016/j.forsciint.2014.07.019
  20. Marchei E, Tini A, Pirani F, Lo Faro AF, Marinelli S. Is GHB-glucuronide useful as a biomarker for the exogenous use of GHB? Eur Rev Med Pharmacol Sci 2019;23:2311–3. doi: 10.26355/eurrev_201903_17369
  21. Solimini R, Rotolo MC, Pellegrini M, Minutillo A, Pacifici R, Busardò FP, Zaami S. Adulteration practices of psychoactive illicit drugs: an updated review. Curr Pharm Biotechnol 2017;18:524–30. doi: 10.2174/1389201018666 170710184531
  22. Pichini S, Marchei E, Pacifici R, Marinelli E, Busardò FP. Chemsex intoxication involving sildenafil as an adulterant of GHB. Drug Test Anal 2017;9:956–9. doi: 10.1002/dta.2054
  23. Busardo FP, Kyriakou C. GHB in biological specimens: which cut-off levels should be taken into consideration in forensic toxicological investigation? Recent Pat Biotechnol 2014;8:206–14. doi: 10.2174/1872208309666150504143155
  24. Beck R, Matanović SM, Zibar L. Gamma-hydroxybutyric acid, gamma-butyrolactone, and 1,4-butanediol addiction: a serious health threat. Arh Hig Rada Toksikol 2019;70:149–50. doi: 10.2478/aiht-2019-70-3295
  25. Laborit H, Jouany JM, Gerard J, Fabiani F. [Summary of an experimental and clinical study on a metabolic substrate with inhibitory central action: sodium 4-hydroxybutyrate, in French]. Presse Med 1960;68:1867–9. PMID: 13758012
  26. Zaytseff A. Über die Reduction des Succinylchlorids [On the reduction of succinyl chloride, in German]. Justus Liebigs Ann Chem 1874;171:258–90. doi:10.1002/jlac.18741710216
  27. Britt GC, McCance-Katz EF. A brief overview of the clinical pharmacology of “club drugs”. Subst Use Misuse 2005;40:1189–201. doi: 10.1081/JA-200066730
  28. Takahara J, Yunoki S, Yakushiji W, Yamauchi J, Yamane Y, Ofuji T. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab 1977;44:1014–7. doi: 10.1210/jcem-44-5-1014
  29. Busardò FP, Jones AW. Interpreting γ-hydroxybutyrate concentrations for clinical and forensic purposes. Clin Toxicol 2019;57:149–63.doi: 10.1080/15563650.2018.1519194
  30. Palatini P, Tedeschi L, Frison G, Padrini R, Zordan R, Orlando R, Gallimberti L, Gessa GL, Ferrara SD. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 1993;45:353–6. doi: 10.1007/bf00265954
  31. Cuypers E, Flanagan RJ. The interpretation of hair analysis for drugs and drug metabolites. Clin Toxicol 2018;56:90–100. doi: 10.1080/15563650.2017.1379603
  32. Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta 2006;370:17–49. doi: 10.1016/j.cca.2006.02.019
  33. Ferrara SD, Tedeschi L, Frison G, Orlando R, Mazzo M, Zordan R, Padrini R, Palatini P. Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. Eur J Clin Pharmacol 1996;50:305–10. doi: 10.1007/s002280050113
  34. Thai D, Dyer JE, Jacob P, Haller CA. Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharmacol Ther 2007;81:178–84. doi: 10.1038/sj.clpt.6100037
  35. Hoes MJ, Vree TB, Guelen PJ. Gamma-hydroxybutyric acid as hypnotic. Clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man. Encephale 1980;6:93–9. PMID: 7449723
  36. Metcalf DR, Emde RN, Stripe JT. An EEG-behavioral study of sodium hydroxybutyrate in humans. Electroencephalogr Clin Neurophysiol 1966;20:506–12. doi: 10.1016/0013-4694(66)90107-6
  37. van Amsterdam JGC, Brunt TM, McMaster MTB, Niesink RJM. Possible long-term effects of γ-hydroxybutyric acid (GHB) due to neurotoxicity and overdose. Neurosci Biobehav Rev 2012;36:1217–27. doi: 10.1016/j.neubiorev.2012.02.002
  38. Morse BL, Morris ME. Toxicokinetics/toxicodynamics of γ-hydroxybutyrate-ethanol intoxication: Evaluation of potential treatment strategies. J Pharmacol Exp Ther 2013;346:504–13. doi: 10.1124/jpet.113.206250
  39. Chin RL, Sporer KA, Cullison B, Dyer JE, Wu TD. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med 1998;31:716–22. doi: 10.1016/S0196-0644(98)70230-6
  40. Ortmann LA, Jaeger MW, James LP, Schexnayder SM. Coma in a 20-month-old child from an ingestion of a toy containing 1,4-butanediol, a precursor of γ-hydroxybutyrate. Pediatr Emerg Car e 2009;25:758–60. doi: 10.1097/ PEC.0b013e3181bec93b
  41. Ingels M, Rangan C, Bellezzo J, Clark RF. Coma and respiratory depression following the ingestion of GHB and its precursors: three cases. J Emerg Med 2000;19:47–50. doi: 10.1016/s0736-4679(00)00188-8
  42. Williams H, Taylor R, Roberts M. Gamma-hydroxybutyrate (GHB): a new drug of misuse. Ir Med J 1998;91:56–7. PMID: 9617031
  43. Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med 1992;156:380–4. PMCID: PMC1003276
  44. Elian AA. Determination of endogenous gamma-hydroxybutyric acid (GHB) levels in antemortem urine and blood. Forensic Sci Int 2002;128:120–2. doi: 10.1016/S0379-0738(02)00183-4
  45. LeBeau MA, Christenson RH, Levine B, Darwin WD, Huestis MA. Intra- and interindividuai variations in urinary concentrations of endogenous gamma-hydroxybutyrate. J Anal Toxicol 2002;26:340–6. doi: 10.1093/jat/26.6.340
  46. Elliott SP. Gamma hydroxybutyric acid (GHB) concentrations in humans and factors affecting endogenous production. Forensic Sci Int 2003;133:9–16. doi: 10.1016/s0379-0738(03)00043-4
  47. Yeatman DT, Reid K. A study of urinary endogenous gamma-hydroxybutyrate (GHB) levels. J Anal Toxicol 2003;27:40–2. doi: 10.1093/jat/27.1.40
  48. Sørensen LK, Hasselstrøm JB. A hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry method for the simultaneous determination of γ-hydroxybutyrate and its precursors in forensic whole blood. Forensic Sci Int 2012;222:352–9. doi: 10.1016/j.forsciint.2012.07.017
  49. Elian AA, Hackett J. Anion exchange SPE and liquid chromatography-tandem mass spectrometry in GHB analysis. J Chromatogr B 2011;879:3752–8. doi: 10.1016/j. jchromb.2011.09.018
  50. Dahl SR, Olsen KM, Strand DH. Determination of γ-hydroxybutyrate (GHB), β-hydroxybutyrate (BHB), pregabalin, 1,4-butane-diol (1,4BD) and γ-butyrolactone (GBL) in whole blood and urine samples by UPLC-MSMS. J Chromatogr B 2012;885–886:37–42. doi: 10.1016/j.jchromb.2011.12.009
  51. Feigenbaum JJ, Howard SG. Naloxone reverses the inhibitory effect of γ-hydroxybutyrate on central DA release in vivo in awake animals: a microdialysis study. Neurosci Lett 1997;224:71–4. doi: 10.1016/s0304-3940(97)13470-x
  52. Devoto P, Colombo G, Cappai F, Gessa GL. Naloxone antagonizes ethanol- but not α-hydroxybutyrate-induced sleep in mice. Eur J Pharmacol 1994;252:321–4. doi: 10.1016/0014-2999(94)90179-1
  53. Thomas G, Bonner S, Gascoigne A. Coma induced by abuse of gamma-hydroxybutyrate (GBH or liquid ecstasy): a case report. BMJ 1997;314:35–6. doi: 10.1136/bmj.314.7073.35
  54. Lee DC, Satz WA, Dougherty T, Greene T. An investigation of flumazenil to antagonize gamma-hydroxybutyrate intoxication in a murine model. J Med Toxicol 2006;2:68–70. doi: 10.1007/bf03161174
  55. Schmidt-Mutter C, Pain L, Sandner G, Gobaille S, Maitre M. The anxiolytic effect of γ-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenil. Eur J Pharmacol 1998;342:21–7. doi: 10.1016/s0014-2999(97)01503-3
  56. Mahr G, Bishop CL, Orringer DJ. Prolonged withdrawal from extreme gamma-hydroxybutyrate (GHB) abuse. Psychosomatics 2001;42:439–40. doi: 10.1176/appi.psy.42.5.439
  57. van Noorden MS, van Dongen LCAM, Zitman FG, Vergouwen TA. Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. Gen Hosp Psychiatry 2009;31:394–6.doi:10.1016/j.genhosppsych.2008.11.001
  58. Miglani JS, Kim KY, Chahil R. Gamma-hydroxy butyrate withdrawal delirium: a case report. Gen Hosp Psychiatry 2000;22:213–5. doi: 10.1016/s0163-8343(00)00071-2
  59. Hutto B, Fairchild A, Bright R. γ-Hydroxybutyrate withdrawal and chloral hydrate. Am J Psychiatry 2000;157:1706. doi: 10.1176/appi.ajp.157.10.1706
  60. Craig K, Gomez HF, McManus JL, Bania TC. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000;18:65–70. doi: 10.1016/s0736-4679(99)00163-8
  61. Gonzalez A, Nutt DJ. Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol 2005;19:195–204. doi: 10.1177/0269881105049041
  62. Hernandez M, McDaniel CH, Costanza CD, Hernandez OJ. GHB-induced delirium: a case report and review of the literature of gamma hydroxybutyric acid. Am J Drug Alcohol Abuse 1998;24:179–83. doi: 10.3109/00952999809001706
  63. McDonough M, Kennedy N, Glasper A, Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004;75:3–9. doi: 10.1016/j.drugalcdep.2004.01.012
  64. World Health Organization (WHO). γ-Butyrolactone (GBL). Who Expert Committee on Drug Dependence. WHO Technical Report Series 973. Geneva: WHO; 2012. p. 14–5.
  65. Koek W, Mercer SL, Coop A. Cataleptic effects of γ-hydroxybutyrate (GHB), its precursor γ-butyrolactone (GBL), and GABAB receptor agonists in mice: Differential antagonism by the GABAB receptor antagonist CGP35348. Psychopharmacology (Berl) 2007;192:407–14. doi: 10.1007/s00213-007-0718-y
  66. Carai MAM, Lobina C, Maccioni P, Cabras C, Colombo G, Gessa GL. γ-Aminobutyric acidB (GABAB-receptor mediation of different in vivo effects of γ-butyrolactone. J Pharmacol Sci 2008;106:199–207. doi: 10.1254/jphs. FP0071487
  67. Goodwin AK, Brown PR, Jansen EEW, Jakobs C, Gibson KM, Weerts EM. Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons. Psychopharmacology (Berl) 2009;204:465–76. doi: 10.1007/s00213-009-1477-8
  68. Busardò FP, Pichini S, Zaami S, Pacifici R, Kintz P. Hair testing of GHB: An everlasting issue in forensic toxicology. Clin Chem Lab Med 2018;56:198–208. doi: 10.1515/cclm-2017-0397
  69. Busardò FP, Kyriakou C, Cipolloni L, Zaami S, Frati P. From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate. Curr Neuropharmacol. 2016;14:17-27. doi: 10.2174/1570159x13666150407225902
  70. Kyriakou C, Pellegrini M, García-Algar O, Marinelli E, Zaami S. Recent trends in analytical methods to determine new psychoactive substances in hair. Curr Neuropharmacol 2016;15:663–81. doi: 10.2174/1570159x15666161111112545
  71. Dornbierer DA, Kometer M, von Rotz R, Studerus E, Gertsch J, Salomé Gachet M, Vollenweider FX, Seifritza E, Bosch OG, Quednow BB. Effects of gamma-hydroxybutyrate on neurophysiological correlates of performance and conflict monitoring. European Neuropsychopharmacology 2019;29:539–48. doi: 10.1016/j.euroneuro.2019.02.004
DOI: https://doi.org/10.2478/aiht-2020-71-3314 | Journal eISSN: 1848-6312 | Journal ISSN: 0004-1254
Language: English, Croatian, Slovenian
Page range: 19 - 26
Submitted on: Jul 1, 2019
Accepted on: Mar 1, 2020
Published on: Apr 9, 2020
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 Enrico Marinelli, Renata Beck, Antonio Malvasi, Alfredo Fabrizio Lo Faro, Simona Zaami, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.